What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JADE101 is supplied as sterile solution to be administered by SC injection.”In the company’s words, NCT07902817 on ClinicalTrials.gov
- Tested for
- IgA Nephropathy (IgAN), IgA Nephropathy
- Main trialPhase 3
- “This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.”In the company’s words, NCT07902817 on ClinicalTrials.gov
Other drugs for IgA Nephropathy (IgAN)
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up3
- May 2027Phase 1 trial completes · ClinicalTrials.gov
- Jan 2029Phase 2 trial completes · ClinicalTrials.gov
- Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 12 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT07059312
- 12 NovCompletion date moved: 2026-10 to 2026-10-21 · ClinicalTrials.gov NCT07059312
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2029 | A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy | |
| Phase 2Recruiting | Jan 2029 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | |
| Phase 1Recruiting | May 2027 | A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants | |
| Phase 1Completed | 21 Oct 2026 | A Phase 1 Study of JADE101 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026